Drugs / Seasonal trivalent split, inactivated influenza vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02935192 | Nov 2016 → Jan 2017 | influenza | Institute of Virology, Vaccines and Sera, Torlak | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Seasonal trivalent split, inactivated influenza vaccine | “Seasonal trivalent split, inactivated influenza vaccine 15 mcg hemagglutinin antigen (HA) of each of A/H1N1; A/H3N2 and B strains; 0.5 mL by IM injection” NCT02935192 ↗ |
| Known as | TIV | “seasonal trivalent split, inactivated influenza vaccine (TIV) in healthy Serbian adults” PMID 32518891 ↗ May 2020 |
| Modality | Vaccine | “seasonal trivalent split, inactivated influenza vaccine” NCT02935192 ↗ |
| Route | Intramuscular | “single intramuscular dose (0.5 ml) of the vaccine” PMID 32518891 ↗ May 2020 |